Kim L.R. Brouwer, Pharm.D., Ph.D., is the William R. Kenan Jr. Distinguished Professor in the Division of Pharmacotherapy and Experimental Therapeutics of the UNC Eshelman School of Pharmacy, associate dean for research and graduate education, and a professor in the curriculum in toxicology.
Kim Brouwer Lab
Dr. Brouwer directs an NIH-funded research program focused on hepatobiliary drug disposition and development and refinement of in vitro model systems to predict in vivo hepatobiliary disposition, drug interactions, and hepatotoxicity. She is a co-inventor of B-CLEAR® (U.S. Patent No. 6,780,580), an in vitro method to assess hepatic uptake, excretion, and biliary clearance that correlates with in vivo data. This technology has been exclusively licensed from the University of North Carolina at Chapel Hill to Qualyst, Inc. Dr. Brouwer is a Qualyst founder and chairs the company’s scientific advisory board.
- Brouwer, KR, Principal Investigator. UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program, sponsored by NIH/NIGMS.
- Brouwer KR, Principal Investigator. Altered Hepatic Disposition of Anionic Drugs: Mechanism, sponsored by NIH.
- Brouwer, KR, Consortium Principal Investigator. Human Cytochrome P450 4F Enzymes and Drug Interactions. Sponsored by NIH/NIGMS.
- Brouwer, KR, Translational Science Advisory Board, Study Section Role: Member, Investigator North Carolina Translational & Clinical Sciences Institute (NC TraCS), sponsored by NIH.
- Brouwer KR, Principal Investigator. Characterization of Hepatic Transporter Interactions with Tolvaptan and Metabolites Sponsored by Otsuka America Pharmaceutical, Inc.
- Brouwer, KR, Subcontract Investigator. PhACTS (Physiologically Accurate Community-Based Framework for Training Systems) will provide a physiology research platform for distributed collaboration and consistent simulation. Sponsored by Applied Research Associates, Inc./Dept. of Defense.
- Brouwer, KR, Subcontractor Co-Principal Investigator. Phase 1 Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics of TTP488. Sponsored by High Point Clinical Trials Center.
- Brouwer, KR, Co-Investigator. UNC Clinical and Translational Science Award, sponsored by NIH.
- Brouwer, KR, Co-Investigator. Short Course: Integrative and Organ Systems Pharmacology, sponsored by NIH.
Dong Fu, Ph.D., is a Research Assistant Professor in the Division of Pharmacotherapy and Experimental Therapeutics. His research interests are liver cell biology and hepatic pharmacology, especially, the cellular processes and the mechanisms that are related to hepatocyte polarization, hepatic transporters trafficking, bile acid signaling, drug-induced mitochondrial and hepatocellular injury and lipids metabolism in hepatocytes.
Lana Tran, PharmD., is a Clinical Research and Drug Development Fellow with the Division of Pharmacotherapy and Experimental Therapeutics. She is interested in hepatic transporter alterations in autosomal dominant polycystic kidney disease and the clinical implications in the disposition of medications that are known substrates of these transporters. She also works on pharmacokinetics/pharmacodynamics of antiretrovirals with a focus on gender, race, and aging effects.
Jessica Murray, PharmD, is a graduate student in the Division of Pharmacotherapy and Experimental Therapeutics.
Her research interests include studying the role of pharmacogenetics, drug metabolism, and drug transport in the development of adverse drug reactions.
Jacqueline Bezençon, Ph.D., is a Postdoctoral Research Associate in the Division of Pharmacotherapy and Experimental Therapeutics. Her research interests are disease- and drug-mediated alterations in hepatic transport of drugs and endogenous compounds (e.g. bile acids) and its impact on drug disposition and toxicity.
Melina Malinen, Pharm.D., Ph.D., is a Postdoctoral Research Associate in the Division of Pharmacotherapy and Experimental Therapeutics. Her research interests are hepatic drug and bile acid transport mechanisms and their role in drug induced liver injury (DILI) and nonalcoholic steatohepatitis (NASH). Especially, development of in vitro studies to characterize the effects of exogenous as well as endogenous compounds on the ADMET of drugs.
Noora Sjöstedt, Ph.D., is a Postdoctoral Research Associate in the Division of Pharmacotherapy and Experimental Therapeutics. Her research interests include understanding the role of transporters on pharmacokinetics, and the integration of in vitro and in silico methods to predict the transporter-mediated drug disposition and drug interactions.
|Patricia Slattum||1992-1994||Pharm.D.Ph.D.||Research Assistant Professor at Virginia Commonwealth University|
|Timothy P. Bradshaw||1992-1993||Ph.D.||Project Manager, Clinical Operations at Pharmaceutical Product Development Inc.|
|David Taft||1993-1994||Ph.D.||Dean, Pharmaceutics at Arnold & Marie Schwartz College|
|Arno Nolting||1995-1997||Ph.D.||Senior Pharmacokineticist at Merck|
|Nita Patel||1998-2000||Ph.D.||Senior Biochemical Pharmacologist at Eli Lilly and Company|
|Pieter Annaert||1998-2000||Ph.D.||Assistant Professor at Catholic University of Leuven, Belgium|
|Yong-Hae Han||2001-2002||Ph.D.||Research Scientist at Bristol-Myers Squibb Pharmaceutical Research Institute|
|Peijin Zhang||2000-2003||M.D.Ph.D.||Senior Pharmacokineticist at Pharmacokinetics/Biostatistics, MPI Research|
|Ken-ichi Nezasa||2004-2005||Ph.D.||Senior Scientist, DMPK, Shionogi Pharmaceuticals, Japan|
|Xianbin Tian||2003-2004||Ph.D.||Principal Investigator, Archemix Corp.|
|Elaine Leslie||2004-2006||Ph.D.||Assistant Professor of Physiology and Laboratory Medicine and Pathology, Membrane Protein Research Group, University of Alberta, Edmonton, Canada|
|Dan Bow||2006-2007||Ph.D.||Senior Research Scientist, Abbott Laboratories|
|Mikko Koskinen||2007||Ph.D.||Laboratory Manager, Orion Corporation ORION PHARMA|
|Koji Abe||2006-2008||Ph.D.||Drug Metabolism and Pharmacokinetics, Sankyo Co., LTD, Japan|
|Kristina Wolf||2006-2009||Ph.D.||Postdoctoral Fellow, UNC Eshelman School of Pharmacy|
|Wei Yue||2006-2007||Ph.D.||Research Assistant Professor, UNC Eshelman School of Pharmacy|
|Betty Hussey||1987-1988||Pharm.D.||Pharmacokineticist at GlaxoSmithKline|
|Patricia E. Warner||1991-1993||Pharm.D.||Regional Medical Scientist, GlaxoSmithKline|
|Kellie L. Schoolar||1992-1994||Pharm.D.||Pharmacokinetics Reviewer, FDA|
|Margaret R. Britto||1992-1994||Ph.D.||Pharmacokineticist, Quintiles, Inc.|
|Katherine H.P. Moore||1993-1995||Pharm.D.||Director, Clinical Pharmacokinetics of Antivirals, GlaxoSmithKline|
|Stephen P. Letrent||1993-1995||Pharm.D.||Director, Clinical Oncology, Pfizer Global Research and Development|
|Mary Beth Mann||1994-1996||Pharm.D.||Pharmacokineticist, GlaxoSmithKline|
|Elizabeth Migoya||1995-1997||Pharm.D.||Clinical Associate, Merck Research Labs|
|Yazdi K. Pithavala||1995-1997||Ph.D.||Pharmacokineticist, Agouron-Pfizer Global R&D|
|Jeffrey D. Fischer||1996-1998||Pharm.D.||Director, Product Services and Support, Pharsight, Inc.|
|Joi Odishaw||1996-1998||Pharm.D.||Director, Clinical Pharmacology, Infinity Pharmaceuticals|
|Kristine M. Radomski||1996-1998||Pharm.D.||Assistant Professor, St. Jude Children’s Research Hospital|
|Paul Mudd||1997-1999||Pharm.D.||Pharmacokineticist, GlaxoSmithKline|
|Min Song||1997-1999||Pharm.D.||Pharmacokineticist, Pfizer, Inc.|
|Matthew Lamb||1998-2000||Pharm.D.||Clinical Pharmacologist, Hoffman-La Roche|
|Chee Ng||1998-2000||Pharm.D.||Director of Pharmacokinetics/Pharmacodynamics, Cancer Therapy and Research Center, San Antonio Cancer Institute|
|Bindu Murthy||1999-2001||Pharm.D.||Manager Clinical Pharmacokinetics, Johnson&Johnson Pharmaceutical Research and Development|
|Daphne Williams||1999-2001||Ph.D.||Senior Clinical Pharmacokineticist, GlaxoSmithKline|
|Susan Ford||2000-2002||Pharm.D.||Pharmacokineticist, GlaxoSmithKline|
|Seth Berry||2000-2002||Pharm.D.||Associate Research Pharmacokineticist, Clinical Pharmacology, Quintiles|
|Christine Brandquist||2001-2003||Pharm.D.M.S.||Senior Scientist, Pharmacokinetics and Biopharmaceutics, GloboMax, ICON Consulting Medeval|
|Adam M. Persky||2002-2004||Ph.D.||Clinical Associate Professor, University of North Carolina|
|Brendan M. Johnson||2003-2005||Ph.D.||Pharmacokineticist, GlaxoSmithKline|
|Lakshmi Vasist||2004-2006||Pharm.D.||Pharmacokineticist, GlaxoSmithKline|
|Todd Dumas||2004-2006||Pharm.D.||Pharmacokineticist, Quintiles Inc.|
|Amar Mehta||2005-2007||Pharm.D.||Law Student, Boston University|
|Grant Hogeland||2005-2007||Pharm.D.||Pharmacokineticist, Quintiles, Inc.|
|Betty Ngo||2006-2008||Pharm.D.||Pharmacokineticist, Quintiles, Inc.|
|Sandra Goss||2006-2008||Pharm.D.Ph.D.||Pharmacokineticist, Abbott Laboratories|
|Ryan Criste||2007-2009||Pharm.D.||Pharmacokineticist, MedImmune|
|Ahsan Rizwan||2008-2010||Ph.D.||Research Scientist, Quintiles|
|Teodora Dumitrescu||2010-2012||Ph.D.||Clinical Pharmacokineticist, Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline|
|Vadryn Pierre||2014-2016||Pharm.D.||Staff Fellow – Clinical Pharmacology Reviewer at the FDA, CDER, OCP, Division V|
|Stephen Greene||2016-2018||Pharm.D.||Clinical Pharmacology Manager, SK Life Science|
|Josh Kaullen||2015-2017||Pharm.D.||Pharmacokineticist, IQVIA|
|James D. Whisnant||1999||M.S.|
|Scott D. Studenberg||1992||Ph.D.||Senior Scientist, GlaxoSmithKline|
|A. Benjamin Suttle||1993||Ph.D.||Research Pharmacokineticist, GlaxoSmithKline|
|Allen E. (Jo) Cato III||1994||Ph.D.||Research Pharmacokineticist, Cato Research, Ltd.|
|Lisa Carlton||1995||Ph.D.||Manager, Regulatory Affairs, Otsuka America Pharmaceuticals, Inc.|
|E. Stacy (Hall) Ward||1996||Ph.D.||Research Scientist: Absorption Systems|
|Kenneth C. Turner||1996||Ph.D.||Pharmacokineticist, Bristol-Myers Squibb Pharmaceutical Research Insistute|
|Catherine L. Booth||1998||Ph.D.||Research Scientist, Merck Research Laboratories|
|Xingrong Liu||1998||Ph.D.||Research Scientist, Roche Palo Alto|
|Stephen P. Letrent||1998||Pharm.D.Ph.D.||Director, Clinical Oncology, Site Head for Oncology Translational Medicine and Clinical Leader for Signal Transduction in Oncology, Pfizer Global Research and Development|
|Hao Xiong||2001||Ph.D.||Group Leader, Department of Clinical Pharmacokinetics, Abbott Laboratories|
|Chee Ng||2002||Pharm.D.Ph.D.||Director of Pharmacokinetics/Pharmacodynamics, Cancer Therapy and Research Center, San Antonio Cancer Institute|
|Ryan Z. Turncliff||2004||Ph.D.||Senior Scientist, Pharmacokinetics, Alkermes, Inc.|
|Keith A. Hoffmaster||2004||Ph.D.||Novartis Institutes for BioMedical Research, Metabolism and Pharmacokinetics|
|Daniel C. Kemp||2004||Ph.D.||Toxicology External Study Manager, GlaxoSmithKline|
|Priyamvada Chandra||2005||Ph.D.||Novartis Institutes for BioMedical Research, Translational Sciences, DMPK PK/PD|
|Cornelia Smith||2005||Ph.D.||Product Characterization Leader, CellzDirect, Inc.|
|Mary Peace McRae||2005||Ph.D.||Assistant Professor, Department of Pharmacology, Kansas City University of Medicine and Biosciences|
|Maciej J. Zamek-Gliszczynski||2006||Ph.D.||Senior Scientist, Eli Lilly and Company|
|Giulia Ghibellini||2006||Ph.D.||Pharmacokineticist, ClinPharm Consulting|
|Patrick Roberts||2007||Ph.D.||Postdoctoral Fellow, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill|
|Jin Kyung Lee||2009||Ph.D.||Research Scientist, Qualyst, Inc.|
|Brandon Swift||2010||Ph.D.||Pharmacokineticist, Allergan|
|Zhixia (Grace) Yan||2007-2011||Ph.D.||Clinical Pharmacology Reviewer, FDA|
|LaToya Griffin||2006 – 2012||Ph.D.||Academic Postdoctoral Fellow, Educational Technology Research and Development, University of North Carolina at Chapel Hill|
|Nathan Pfeifer||2008 – 2013||Pharm.D.||Senior Clinical Pharmacokineticist II, AbbVie|
|Christina Mayer||2011 – 2013||Pharm.D.||Scientist, Pharmacokinetics & Pharmacodynamics, Biologics Clinical Pharmacology, Janssen Research & Development|
|Mario Sampson||2011 – 2013||Ph.D.||Pharmacokinetics Reviewer, Clinical Pharmacology, US FDA|
|Brian C. Ferslew||2009 – 2014||Ph.D.||Scientist, Clinical Pharmacology and Drug Metabolism and Pharmacokinetics, Theravance Biopharma|
|Curtis Johnston||2012 – 2014||Pharm.D.||Pharmacometrics Bootcamp Scientist, Metrum Research Group LLC|
|Kyunghee Yang||2010 – 2014||Ph.D.||Postdoctoral Fellow, Hamner-UNC Institute for Drug Safety Sciences|
|Jason Robert Slizgi||2012 – 2016||Ph.D.|
|Kevin Watt||2011-2017||Ph.D.||Assistant Professor at Duke University School of Medicine, Department of Pediatrics|
|Cen Guo||2013-2018||Ph.D.||Clinical Pharmacologist, Oncology, Pfizer|